No such message found

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Two big thank you’s

Very good info.

I think Zen used to provide a letter stating an estimated value once a year on it's faq but I no longer see it there. They may have removed it when the shares began trading OTC.

The overcontribution penalties are steep by design, not something you want to stumble into accidentally.

Share
New Message
Please login to post a reply